1. Home
  2. BOLD vs NMTC Comparison

BOLD vs NMTC Comparison

Compare BOLD & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • NMTC
  • Stock Information
  • Founded
  • BOLD 2018
  • NMTC 2009
  • Country
  • BOLD United States
  • NMTC United States
  • Employees
  • BOLD N/A
  • NMTC N/A
  • Industry
  • BOLD
  • NMTC Medical/Dental Instruments
  • Sector
  • BOLD
  • NMTC Health Care
  • Exchange
  • BOLD Nasdaq
  • NMTC Nasdaq
  • Market Cap
  • BOLD 24.4M
  • NMTC 33.8M
  • IPO Year
  • BOLD 2024
  • NMTC N/A
  • Fundamental
  • Price
  • BOLD $1.17
  • NMTC $0.74
  • Analyst Decision
  • BOLD Buy
  • NMTC Strong Buy
  • Analyst Count
  • BOLD 3
  • NMTC 1
  • Target Price
  • BOLD $4.00
  • NMTC $1.45
  • AVG Volume (30 Days)
  • BOLD 286.6K
  • NMTC 178.3K
  • Earning Date
  • BOLD 08-11-2025
  • NMTC 08-13-2025
  • Dividend Yield
  • BOLD N/A
  • NMTC N/A
  • EPS Growth
  • BOLD N/A
  • NMTC N/A
  • EPS
  • BOLD N/A
  • NMTC N/A
  • Revenue
  • BOLD N/A
  • NMTC $5,758,777.00
  • Revenue This Year
  • BOLD N/A
  • NMTC $157.28
  • Revenue Next Year
  • BOLD N/A
  • NMTC $41.79
  • P/E Ratio
  • BOLD N/A
  • NMTC N/A
  • Revenue Growth
  • BOLD N/A
  • NMTC 54.53
  • 52 Week Low
  • BOLD $1.00
  • NMTC $0.40
  • 52 Week High
  • BOLD $4.72
  • NMTC $1.39
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • NMTC 60.04
  • Support Level
  • BOLD N/A
  • NMTC $0.71
  • Resistance Level
  • BOLD N/A
  • NMTC $0.77
  • Average True Range (ATR)
  • BOLD 0.00
  • NMTC 0.05
  • MACD
  • BOLD 0.00
  • NMTC 0.00
  • Stochastic Oscillator
  • BOLD 0.00
  • NMTC 65.90

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About NMTC NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Share on Social Networks: